Pharmaceuticals & Biotechnology | Pharma & Biotech Resources
Summary: Pharma IQ, a division of IQPC, is an international online community focusing on providing pharmaceutical professionals with knowledge, information and articles. We are dedicated to creating a learning environment for sharing ideas, best practices and solutions within the pharmaceutical community Through Pharma IQ, you will be able to access pharmaceutical information resources such as
- Visit Website
- RSS
- Artist: Unknown
Podcasts:
Dr. Barbara J. Potts, Senior Consultant, Potts and Nelson Consulting, joins Andrea Charles from Pharma, IQ to discuss the biggest threats to the safety of biologics and which contaminants present the most problems. Potts also shares her insights on common myths surrounding
Ottavio Arancio, Professor, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, Columbia University, speaks to Andrea Charles from Pharma IQ, about the goals of his current research, how the landscape for Alzheimer's disease drug discovery has
As major patents on blockbuster drugs continue to expire, Chris Hayes, Senior Advisor, Intellectual Property Rights - Launched Products, Lundbeck, and Andrea Charles from Pharma IQ discuss how return-on-investment can be maximised and the key drivers for IP strategy. In this podcast,
Kimberly Myers, Office of Biorepositories and Biospecimen Research, National Cancer Institute, NIH, DHHS, joins Andrea Charles from Pharma IQ, for an update on the progess of the NCI's Centre for Biospecimen Science and Standards, and how it fits into the greater
Markus Duerring, IT Account Manager, Novartis Institutes for BioMedical Research, joins Andrea Charles from Pharma IQ, to discuss trends currently shaping the pharma data and knowledge management landscape, key selection criteria for choosing an electronic
In this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fund orphan drugs at a time of austerity measures. Macarthur also shares his
Helmut Schuetz of BEBAC Consultancy and Anders Fuglsang of Fuglsang Pharma Consultancy, join Pharma IQ to discuss the impact of the bioequivalence guidelines introduced in summer 2010 on the pharmaceutical industry. In this debate, we get the views of two key consultants within the field
"Most organisations looked at security over the last couple of years and personal devices wouldn’t have been allowed if it’s portable and encrypted. So we’ve turned things around there. Obviously corporate equipment is still encrypted but we’ve developed ways
Gagan Bhradwaj, General Manager-Procurement & Supply Management, Zydus Cadila India, speaks to Andrea Charles from Pharma IQ, about the main challenges for clinical trial supply in Asia now and how the industry is addressing these challenges throughout the supply chain.
Claus Duedal Pedersen, Head of Centre for Clinical Innovation Odense University Hospital speaks to Andrea Charles from Pharma IQ, about effectively utilising telemedicine and increasing pan-European patient-provider cooperation through RENEWING HEALTH (REgioNs of Europe
The Merck High Throughput Research Facility investigates alternative compound management strategies. One of these is DMSO Hydration. In this Pharma IQ podcast we talk to Ed Hudak, Sr. Research Engineer at Merck & Co., where research is being done to saturate DMSO – and the
Healthcare providers across the EU are looking forward to the day when e-health collaboration is a reality and data can flow freely yet securely across institutional and international boundaries. Healthcare IT personnel are working toward this goal by the careful
In the context of research involving biobanks , informed consent fails in the two most salient dimensions: in its usual format, informed consent both inhibits important research and yet also fails to protect research participants in some important ways. Given these failures, new ways of
In this Pharma IQ interview Nabil Al-Tawil, Principal Investigator of the Phase I Unit at Karolinska University Hospital, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase 1 clinical development. Al-Tawil explains the importance of benchmarking the
In this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical development and optimisation of biomarker development strategies. Vercruysse discusses biomarker
